Clinical trials
Paraganglioma clinical trials
Below are recruiting paraganglioma clinical trials, each written for real people, not researchers. We’re tracking 26 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03160274Recruiting
Genetic testing for certain adrenal and nerve tumors
This study looks at genetic (DNA) changes in people with pheochromocytoma or paraganglioma and related conditions. It may help clarify why these conditions happen and how they run in families.
San Antonio, TexasAges Any age - NCT03206060RecruitingPhase 2
Lu-177 DOTATATE for hard-to-remove pheochromocytoma or paraganglioma
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
Bethesda, MarylandAges 18–100 - NCT03344016Recruiting
Study of pheochromocytoma and paraganglioma in patients
This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.
ZurichAges 5 years+ - NCT05636540RecruitingEarly Phase 1
PET/CT scan test for a tumor protein in these rare tumors
This early study uses a special PET/CT scan to see how much a specific cancer-related protein (PARP-1) is present in pheochromocytoma and paraganglioma. It may help doctors understand the biology of these tumors and how useful this scan could be in the future.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT07282587RecruitingPhase 2
Study of ONC206 for advanced pheochromocytoma and paraganglioma
This trial tests an oral drug called ONC206 (JZP3507) for people with advanced pheochromocytoma or paraganglioma that cannot be removed with surgery. It may be an option if you've already tried standard treatments or cannot take them.
Los Angeles, CaliforniaAges 18 years+ - NCT06408402Recruiting
Environment and tumor risk in SDHx carriers
This study looks at whether things in the environment (like chemicals or lifestyle) affect the risk of developing certain tumors in people who have a change in their SDHx gene. It compares people with the gene change who have had a related tumor to those who haven't.
AngersAges 18 years+ - NCT03050268Recruiting
Study of childhood cancer risk in families
This study looks at inherited (family) risk for childhood cancers, including families with early cancers or known cancer risk conditions. It may help researchers understand why some children get cancer and improve future risk detection and care.
Memphis, TennesseeAges Any age - NCT04081701RecruitingPhase 4
Ga-68 DOTATATE PET/MRI for somatostatin-receptor brain tumors
This trial tests how well a special scan (Ga-68 DOTATATE PET combined with MRI) helps diagnose and guide treatment for certain brain tumors that have somatostatin receptors. It may help doctors better find tumor recurrence or remaining tumor after treatment.
New York, New YorkAges 18–100 - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT05069220RecruitingEarly Phase 1
PET/CT scan to study neural crest tumors
This early-phase trial uses a special PET/CT scan to help evaluate neural crest tumors, which include conditions like neuroblastoma. It may help doctors understand how well the scan shows tumor activity to guide diagnosis and treatment planning.
Beijing, DongchengAges 1–80 - NCT05636618RecruitingPhase 1/Phase 2
Targeted radiation for certain receptor-positive tumors
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Jacksonville, FloridaAges 18–90 - NCT05702944RecruitingPhase 4
Skipping pre-surgery blood pressure medicine for certain adrenal tumors
This trial studies whether it is safe to skip a specific pre-surgery blood pressure medicine (alpha-blocker) for people with normal blood pressure who have a pheochromocytoma or paraganglioma in one adrenal gland. It aims to see if fewer pre-op meds can still prevent risky blood pressure surges during surgery.
SeoulAges 19–70 - NCT06045260RecruitingPhase 2
Lu-177 Dotatoc for neuroendocrine and other sst2-positive cancers
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
Cesena, Forlì-CesenaAges 18 years+ - NCT06377033Recruiting
Using health records to advance genomic medicine for all
This study uses electronic health records to learn how to improve genomic medicine across a diverse health system. It may help make DNA-based healthcare more accessible and effective for people with certain conditions.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06444607Recruiting
Immune study of hereditary pheochromocytoma tumors
This study looks at how the immune system responds to rare adrenal or nerve-related tumors (pheochromocytoma and paraganglioma). Researchers want to understand the tumor's environment, which may help improve future treatments.
Nijmegen, GelderlandAges 18 years+ - NCT06523582Recruiting
Genetic study of neuroendocrine tumors in Mexican patients
This study aims to find genetic causes of neuroendocrine tumors in Mexican patients. By understanding your DNA, researchers hope to improve diagnosis and treatment for people with these rare conditions.
Mexico City, Mexico CityAges 18 years+ - NCT06573723Recruiting
Rare disease registry at Hospital Italiano
This study collects information from patients with certain rare diseases to better understand them. If you have one of these conditions and receive care at Hospital Italiano de Buenos Aires, you may be able to join.
Buenos Aires, Buenos AiresAges Any age - NCT07072143Recruiting
Study on children with rare tumors
This study is looking at children and teens with very rare tumors to learn more about these conditions and improve future care. It aims to gather information from patients treated at participating centers.
Padova, ItalyAges birth–18 years - NCT07195500Recruiting
Imaging scans for neuroblastoma and related tumors
This trial uses special PET/CT or SPECT/CT scans that light up certain types of tumor cells (neuroblastoma and pheochromocytoma/paraganglioma). The scans help doctors see where the cancer is, how far it has spread, and whether treatment is working.
Nanjing, JiangsuAges 6 months+ - NCT07680205RecruitingPhase 2
Study of Belzutifan for Pheochromocytoma or Paraganglioma
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
Cambridge, CambridgeshireAges Any age - NCT07288931Recruiting
PET/CT Scan for Pheochromocytoma and Paraganglioma
This trial uses a special PET/CT scan called Al18F-NOTA-LM3 to help doctors see pheochromocytoma and paraganglioma tumors more clearly. It may help find out if you have these tumors and guide your treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT00107289RecruitingPhase 2
MIBG radioactive iodine treatment for hard-to-treat childhood tumors
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
New York, New YorkAges 1 year+ - NCT06427798RecruitingPhase 1/Phase 2
Radioactive drug for previously treated gut or adrenal tumors
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
Bethesda, MarylandAges 18–120
Hear when a new Paraganglioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Paraganglioma trials by city
Studies with a site in or near these metro areas.
Paraganglioma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for paraganglioma?
- Yes. Clin2 currently lists 26 recruiting paraganglioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a paraganglioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a paraganglioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.